A prospective, real world, observational study, evaluating the effects of elexacaftor-tezacaftor-ivacaftor in Cystic fibrosis patients with advanced pulmonary disease
Latest Information Update: 01 Mar 2021
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2021 New trial record
- 18 Feb 2021 Results published in the American Journal of Respiratory and Critical Care Medicine